Year: 1947
Type: article
Abstract: In the present series skin rashes have occurred in six patients: in four the drug was given again without causing reappearance of the rash, and in two the rash reappeared and the thiocyanate had to be stopped.Koffler and Freireich (1944) have reported femoral thrombophlebitis -in four of a series of 40 cases treated, and observed that the lesion tended to recur if the drug was repeated.In the present series this complication has occurred twice.In a larger series of other cases under the observation of one of us it has not bccurred at all.Goitre is reported to have followed the long-continued administration of potassium thiocyanate.Wald et al. ( 1939) report 11 cases in 246 patients treated.We have not seen this complication.Our opinion is that, apart from skin rashes which may occur at low serum thiocyanate concentrations, toxic effects are uncommon provided that the dosage of the drug is properly controlled.The necessity for close control, especially in the early stages of thiocyanate therapy during which the adequate maintenance dose is being ascertained, cannot be over-emphasized.It is said that thiocyanate therapy may be responsible for retinal, cerebral, and coronary thrombosis, but this opinion takes no account of the fact that a proportion of patients with persistent hypertension are suffering from active arteriosclerotic disease and that this disease is the cause, or may be the cause, of thrombotic phenomena occurring during the administration of thiocyanate. SummaryAn attempt has been made to assess the value of thiocyanate therapy in hypertension.A scheme of dosage has been given together with indications for treatment.Patients with hyper- tension have been classified according to phases and types of hypertensive disease.Taking the cases as a whole, sympto- matic relief and a significant fall in blood pressure were observed in roughly 60% of the cases.The further observation of 42 patients shows that the effect of thiocyanate therapy can be correlated with the phases of the arteriosclerotic process, and that whereas symptomatic relief is given and blood-pressure reduction is maintained in approximately 40% of the cases, the continued administration of potassium thiocyanate does not prevent, in individual cases at least, the continued progress of arteriosclerotic disease.
Source: BMJ
Author: G. B. Forbes
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2003296056
